Malaria is common in areas such as Africa, South America, and Southern Asia. This medicine is not effective against all strains of malaria. Hydroxychloroquine flu vaccine Medicine plaquenil 200 mg In 2014, its efficacy to treat Sjögren syndrome was questioned in a double-blind study involving 120 patients over a 48-week period. Hydroxychloroquine is widely used in the treatment of post-Lyme arthritis. It may have both an anti-spirochaete activity and an anti-inflammatory activity, similar to the treatment of rheumatoid arthritis. Jun 09, 2017 Wolpin BM, Rubinson DA, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;7–638. Pantziarka P et al 2014 The Repurposing Drugs in Oncology ReDO project Ecancer Medical Science 8 442 PMID 25075216 PMCID 4096030. 139. Buch I et al 2016 Schedule-dependent synergy of chloroquine with chemotherapy for anti-cancer treatment Cancer Research and Oncology Open Access 22 140. Taking hydroxychloroquine long-term or at high doses may cause irreversible damage to the retina of your eye. Hydroxychloroquine is also an antirheumatic medicine and is used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. Wolpin oncologist 2014 hydroxychloroquine Full text Evidence-based complementary treatment of., Full text Effects of chronic exposure of hydroxychloroquine. Plaquenil maculopathy rateInteraction of plaquenil with other drugs Brian M. Wolpin is supported by NIH Grant K07 CA140790 from the National Cancer Institute, an American Society of Clinical Oncology Career Development Award, a Howard Hughes Medical Institute Early Career Physician‐Scientist Award, the Lustgarten Foundation, and Promises for Purple. Phase II and Pharmacodynamic Study of. - The Oncologist. Repurposing Drugs in Oncology ReDO—chloroquine and.. Phase Ib/II study of hydroxychloroquine in combination with.. Patients received 400 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision. Patients received 600 mg hydroxychloroquine orally twice per day. Over the last decade, a dozen Phase I and I/II clinical trials have been completed and published using the autophagy inhibitors, Chloroquine CQ or hydroxychloroquine HCQ in cancer. These lysosomal targeting compounds were originally approved for use in humans as anti-malarial drugs but have been repurposed as autophagy targeting cancer. Wolpin BM, Rubinson DA, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 2014; 196 637-8.